share_log

Biora Therapeutics | 424B5: Prospectus

Biora Therapeutics | 424B5: Prospectus

Biora Therapeutics | 424B5：募资说明书
SEC announcement ·  04/02 16:46
Moomoo AI 已提取核心信息
Biora Therapeutics, Inc. has filed a prospectus supplement on April 2, 2024, which updates and amends certain information from the original prospectus dated February 7, 2023. The supplement pertains to the resale offering of 90,000 shares of common stock, issuable upon the exercise of warrants. The company has entered into a Warrant Amendment Agreement with an institutional investor to amend the exercise price of the warrants from $8.22 to $1.10 per share. Additionally, the amended warrants will not be exercisable until Biora Therapeutics receives stockholder approval for the issuance of shares upon exercise of the warrants, and the expiration date of the warrants has been extended to five years post-approval. The amendments took effect on March 31, 2024, and the last reported sale price of Biora Therapeutics' common stock on the Nasdaq Global Market was $1.10 per share as of March 28, 2024.
Biora Therapeutics, Inc. has filed a prospectus supplement on April 2, 2024, which updates and amends certain information from the original prospectus dated February 7, 2023. The supplement pertains to the resale offering of 90,000 shares of common stock, issuable upon the exercise of warrants. The company has entered into a Warrant Amendment Agreement with an institutional investor to amend the exercise price of the warrants from $8.22 to $1.10 per share. Additionally, the amended warrants will not be exercisable until Biora Therapeutics receives stockholder approval for the issuance of shares upon exercise of the warrants, and the expiration date of the warrants has been extended to five years post-approval. The amendments took effect on March 31, 2024, and the last reported sale price of Biora Therapeutics' common stock on the Nasdaq Global Market was $1.10 per share as of March 28, 2024.
Biora Therapeutics, Inc.已于2024年4月2日提交了招股说明书补充文件，其中更新和修订了2023年2月7日最初招股说明书中的某些信息。该补编涉及90,000股普通股的转售发行，可在行使认股权证时发行。该公司已与机构投资者签订了认股权证修订协议，将认股权证的行使价从每股8.22美元修改为1.10美元。此外，在Biora Therapeutics在行使认股权证后获得股东批准发行股票之前，修改后的认股权证将不可行使，并且认股权证的到期日已延长至批准后的五年。修正案于2024年3月31日生效，截至2024年3月28日，Biora Therapeutics在纳斯达克全球市场上公布的普通股销售价格为每股1.10美元。
Biora Therapeutics, Inc.已于2024年4月2日提交了招股说明书补充文件，其中更新和修订了2023年2月7日最初招股说明书中的某些信息。该补编涉及90,000股普通股的转售发行，可在行使认股权证时发行。该公司已与机构投资者签订了认股权证修订协议，将认股权证的行使价从每股8.22美元修改为1.10美元。此外，在Biora Therapeutics在行使认股权证后获得股东批准发行股票之前，修改后的认股权证将不可行使，并且认股权证的到期日已延长至批准后的五年。修正案于2024年3月31日生效，截至2024年3月28日，Biora Therapeutics在纳斯达克全球市场上公布的普通股销售价格为每股1.10美元。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息